Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator
|
|
- Marianna Johnson
- 5 years ago
- Views:
Transcription
1 Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator at LAUMCRH
2 Review the mechanism of action, indications and contraindications of new oral anticoagulants Identify patients who may benefit from the new oral anticoagulants Discuss available monitoring and reversibility of NOACS Discuss important counseling tips & initiatives to consider
3 AC: Anticoagulation NOACS: Novel oral anticoagulants SPAF: Stroke prevention in Atrial Fibrillation VTE: Venous thromboembolism DVT: Deep venous thrombosis PE: Pulmonary embolus Hb/Hct: hemoglobin/hematocrit PK and PD: pharmacokinetic and pharmacodynamic
4 Saraf K, et al. Postgrad Med J 2014;90:
5 impairment VKAS (ACENOCOUMAROL, HYDROXYCOUMAROL) Variability in dosing More monitoring Long half life Numerous drug/food interactions NOACS ( RIVAROXABAN, DABIGATRAN, APIXABAN) Fixed dosing Less monitoring Shorter half lives compliance is important Less drug food interactions Dosage adjustment required for renal
6 Dabigatran Rivaroxaban Apixaban Available in Lebanon Yes Yes Soon! CHEST 2012; 141(2)(Suppl):e120S e151s Target Thrombin Factor Xa Factor Xa Bioavailability Frequency Bid Bid or daily bid T- max (h) Half life (h) Protein binding(%) CYP metabolism (%) None P-gp transport Yes Yes yes Renal excretion (%) Non renal excretion(%)
7 CHEST 2012; 141(2)(Suppl):e24S e43s Oral Anticoagulant Routine laboratory test Other monitoring parameters VKA Antagonists PT/ INR LFTs Oral DTI (Dabigatran) No routine test SrCr Direct Xa inhibitor (Rivaroxaban) No routine test SrCr Direct Xa inhibitor (Apixaban) No routine test SrCr
8 Stroke prevention in Atrial Fibrillation (SPAF) Treatment of VTE (PE and DVT) Thromboprophylaxis in orthopedic patients
9 Stroke prevention in Atrial Fibrillation (SPAF) Treatment of VTE (PE and DVT) Thromboprophylaxis in orthopedic patients
10 MM is a 67 year old woman who underwent a mechanical mitral valve replacement 7 months ago. She presents to clinic with atrial fibrillation and during work up expresses interest in being started on rivaroxaban instead on acenocoumarol. Creatinine Clearance ~ 90ml/min. At home is on: acenocoumarol regimen: MWFSS 2mg & TTH 3mg INR goal Last INR ( 1 week ago, 2.7) Which of the following is the best treatment plan for this patient? A. Switch to rivaroxaban 20mg po daily B. Switch to rivaroxaban 15 mg po daily C. Switch to dabigatran 150mg po bid D. Keep on acenocoumarol
11 Data randomized controlled trials (~ 70,000 patients) Majority are non-inferiority trials in terms of decrease in stroke (Ischemic & hemorrhagic) in comparison to VKA Less incidence of intracranial hemorrhage NOACs are associated with an increase in GI bleeds as compared to warfarin
12 Non-valvular atrial fibrillation + Indication for Anticoagulation Dose adjustments of NOACS are necessary for renal impairment in Stroke Prevention in Atrial Fibrillation (SPAF)
13 RELY ROCKET-AF ARISTOTLE Two doses studied 150mg PO BID 110mg PO BID 20mg po daily reduced to 15 mg po daily 5mg po BID reduced to 2.5mg po BID Not studied in CrCl< 30ml/min Approved on the market is also 75mg po BID If CrCl30-50 ml/min If ANY TWO: If age 80 years If weight 60kg If SrCr 1.5mg/dl
14
15 N= 256 patients Terminated early: The use of dabigatran in patients with mechanical heart valves was associated with increased rates of thromboembolic and bleeding complications, as compared with warfarin, thus showing no benefit and an excess risk. N ENGL J MED 369;13 september 26, 2013
16
17 Valvular Indications and Contraindications to NOACs in Afib Contraindicated for NOACS Mechanical prosthetic heart valves Mitral stenosis(moderate to severe) Eligible for NOACS Other native valve diseases (mild to moderate) Severe aortic stenosis Bioprosthetic heart valves (except in the first 3 months) Mitral valve repair (except in the first 3-6 months) Europace doi: /europace/euv309
18 Europace doi: /europace/euv309
19 Mechanism of interaction: cytochrome P450 3A4 and P- glycoprotein (P-gp) Concern: minimal guidance for dose adjustments & monitoring is not possible Interacting medications: Antimicrobials (antifungals, antibiotics, antiretrovirals) Antiepileptics Immunosuppressant Verapamil
20 Contraindicated medication Verapamil Protease inhibitors Cyclosporin Tacrolimus Itraconazole Ketoconazole Posaconazole Voriconazole Fluconazole- unknown Reason for contraindication Increases levels by % Increase levels- unknown Increases levels by % Dosing suggested by US labeling If normal renal function, consider dosing at 110mg po BID instead of 150mg po bid US labeling: 75 mg PO BID if CrCl 30-50ml/min Rifampicin Carbamazepine Phenobarbital Phenytoin Lower dabigatran levels by 66% Europace. European Heart & Rhythm Association doi: /europace/euv309
21 Approved for non-valvular atrial fibrillation Imperative to dose adjust in renal dysfunction Less intracranial hemorrhage but more gastrointestinal bleeding ( except apixaban) Necessitate that pharmacists screen for drug interactions
22 MM is a 67 year old woman who underwent a mechanical mitral valve replacement 7 months ago. She presents to clinic with atrial fibrillation and during work up expresses interest in being started on rivaroxaban instead on acenocoumarol. Creatinine Clearance ~ 90ml/min. At home is on: acenocoumarol regimen: MWFSS 2mg & TTH 3mg INR goal Last INR ( 1 week ago, 2.7) Which of the following is the best treatment plan for this patient? A. Switch to rivaroxaban 20mg po daily B. Switch to rivaroxaban 15 mg po daily C. Switch to dabigatran 150mg po bid D. Keep on acenocoumarol
23 Stroke prevention in Atrial Fibrillation (SPAF) Treatment of VTE (PE and DVT) VTE Prophylaxis in orthopedic patients
24 Randomized controlled trials (~ 25,000 patients) Non-inferior to conventional treatment for VTE recurrence(margins of non-inferiority between ) Less bleeding (notably more GI bleeding, except apixaban) Superior to placebo for the prevention of recurrent VTE and are associated with lower bleeding rates. J Thromb Thrombolysis (2015) 39: Blood 2014;124(7):
25 2012 ACCP Guidelines NOACs (dabigatran and rivaroxaban) as an option Provides weak recommendation in favor VKA/parenteral anticoagulation(conventional treatment) 2014 ESC Guidelines NOACS as alternatives to conventional anticoagulation for the acute treatment, first three months and extended treatment(>3 months) Konstantinides et al. European Heart Journal. doi: /eurheartj/ehu283 CHEST 2012; 141(2)(Suppl):e419S e494s
26 A 70 yo woman (wt=80kg, ht=173cm) is diagnosed with a DVT. No significant PMH. Pertinent history is that she s not very active and had recent travel. Her CrCl is estimated at 25ml/min. Which of the following treatment choices is most suitable for this patient? A. Enoxaparin that is bridged to acenocoumarol 2mg po daily B. Rivaroxaban 15mg po BID for 21 days followed by 20mg po daily C. Enoxaparin for 7 days followed by Dabigatran 150mg po BID D. Dabigatran 150mg po BID
27 DVT or PE + Good renal function defined as CrCl( 30 ml/min) NO DOSE ADJUSTMENTS EXIST for CrCL < 30ml/min for Apixaban, Dabigatran or Rivaroxaban in the treatment of VTE
28 Management Strategies Bridging: Parenteral anticoagulant + bridge to oral therapy VKA Directly oral treatment: Rivaroxaban 15mg PO BID for 21 days, followed by 20mg PO daily Apixaban 10 mg PO BID for 7 days followed by 5 mg PO BID Switching: Start parenteral anticoagulant for 1-2 weeks, then switch to Dabigatran 150mg PO BID Start parenteral anticoagulant, then switch to Edoxaban 60mg po daily or if impared renal function (CrCrl 30-50ml/min, weight<60kg or taking potent pgp inhibitors) 30mg PO daily
29 Blood 2014;124(7):
30 Blood 2014;124(7):
31 Patients who should NOT receive NOACS Severe renal impairment defined as: CrCl<30 ml/min for rivaroxaban, dabigatran and edoxaban; and <25 ml/min for apixaban VTE in the setting of Cancer VTE in the setting of thrombophilic conditions When compliance is a concern Blood 2014;124(7): Konstantinides et al. European Heart Journal. doi: /eurheartj/ehu283
32 Patients who should NOT receive NOACS History of GI bleeds Nursing mothers Pregnancy Extreme body weight Blood 2014;124(7): Konstantinides et al. European Heart Journal. doi: /eurheartj/ehu283
33 Appropriate candidates for NOACS On VKA antagonists with erratic INRs Those who find INR testing burdensome Reliable and compliant patients Blood 2014;124(7):
34 Patient specific criteria Prefers to avoid injections CrCl between ml/min Dyspepsia or GERD NOAC selection Apixaban or Rivaroxaban Apixaban, rivaroxaban, edoxaban (not dabigatran) Rivaroxaban, apixaban, edoxaban Recent GI bleed Poor compliance with twice daily dosing Recent myocardial infarction Apixaban Rivaroxaban or edoxaban Rivaroxaban, apixaban,edoxaban Blood 2014;124(7):
35 NOAC US Dosing European Dosing Dabigatran After 5-10 days of parenteral Rivaroxaban 150 mg PO BID (caution with pgp inhibitors and in elderly patients) 15 mg PO BID for 3 weeks, followed by 20mg PO Daily Apixaban 10 mg PO BID for 7 days, followed by 5 mg PO BID (once 6 months have been given, switch to 2.5 mg PO BID for extended treatment) Edoxaban After 5-10 days of parenteral 60 mg po daily Patient weight 60 kg: 30 mg PO daily specific P-gp inhibitors (ie, verapamil, quinidine; azithromycin, clarithromycin, erythromycin, itraconazole, ketoconazole): 30 mg once daily 150 mg PO BID or 110 mg PO BID for patients >80 years of age or on verapamil 15 mg PO BID for 3 weeks, followed by 20mg PO Daily 10 mg PO BID for 7 days, followed by 5 mg PO BID 2.5 mg PO BID for extended treatment Lexicomp 2015 Konstantinides et al. European Heart Journal. doi: /eurheartj/ehu283
36 Interacting medications: Antimicrobials (antifungals, antibiotics, antiretrovirals) Antiepileptics Immunosuppressants Verapamil Amiodarone In general, avoid NOACs with interacting medications in VTE treatment Adjustments based on PK and PD analyses Not studied in the clinical setting of VTE Edoxaban was actually studied to account for dose adjustments in VTE (Dabigatran):EPARProduct Information ;(Apixaban):EPARProduct Information ;(Rivaroxaban) :EPAR Product Information
37 Verify appropriate renal function CrCl> 30ml/min Screen for interactions & caution providers Remember the strategies: Start directly oral therapy with Rivaroxaban or Apixaban If dabigatran or edoxaban are selected, the first week should be parenteral treatment, then SWITCH to NOACS Avoid in special populations: cancer, pregnancy, thrombophilic conditions, extreme body weight Emphasize on compliance, especially the switch in doses
38 A 70 yo woman (wt=80kg, ht=173cm) is diagnosed with a DVT. No significant PMH. Pertinent history is that she s not very active and had recent travel. Her CrCl is estimated at 25ml/min. Which of the following treatment choices is most suitable for this patient? A. Enoxaparin that is bridged to acenocoumarol 2mg po daily B. Rivaroxaban 15mg po BID for 21 days followed by 20mg po daily C. Enoxaparin for 7 days followed by Dabigatran 150mg po BID D. Dabigatran 150mg po BID
39
40 Questions to consider asking Dose of the NOAC Time of last dose with respect to renal function Usually takes hours for the drug to be out of the system if >12 h possible to wait for the drug to clear while monitoring and managing with supportive care Factors influencing plasma concentrations Any P-gp therapy, cyp inhibitors, CKD, renal function Baseline Hct/Hb and platelet count
41 Factors to consider: CrCl, half life & bleeding risk Renal function (CrCl ml/min) Half-life (hours) Timing of discontinuation after last dose of dabigatran before surgery Standard risk of bleeding High risk of bleeding (major surgery, spinal procedure or placement of epidural or spinal cath) >80 13 (11-22) 24 h 2-4 days >50 to (12-34) 24 h 2-4 days >30 to (13-23) 48h 4 days (22-35) 2-5 days >5 days Thrombosis and Haemostasis 103.6/2010 Pradaxa (Package Insert). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals,Inc2010
42
43 Agents Target Structure Route MOA Idarucizumab FDA approval on for Emergency Reversal Dabigatran Humanized monoclonal antibody fragment IV Binds to Dabigatran with a high affinity (~350 times > thrombin) Andexanet alfa fxa inhibitors Modified recombinant from of fxa IV Binds to fxa inhibitors with affinity similar to that of native fxa Aripazine (PER 977) Universal -fxa inhibitors -Dabigatran -UFH, LMWH Small synthetic molecule IV Binds to oral anticoagulants and heparin and reverses the anticoagulant effects Mo Y. Pharmacotherapy 2015;35:201. Ansell JE, et al. N Eng J Med 2014:371:
44
45 Involve your patient Compliance frequency of medication Importance of follow up even if no INR checks Inform the doctor about new medications Missed doses How to take the medication How to store the medication In case of bleeding, share with physician time of last dose and renal function
46 Dabigatran Do not crush or chew tablets Do not open or sprinkle the capsule Avoid in patients with GERD, history of GI bleed, MI Rivaroxaban Take with food You can crush tablets Avoid in history of GI bleed Apixaban You can crush tablets
47
48
49
50
51 NOACS have provided a significant advancement in oral anticoagulation Appropriate patient selection is mandatory SPAF: non-valvular atrial fibrillation and dose adjust for renal impairment VTE: renal impairment is a contraindication, no dose adjustments are available
52
What s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationDIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING
DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING KATHERINE STIRLING CONSULTANT PHARMACIST ANTICOAGULATION AND THROMBOSIS DR LISHEL HORN CONSULTANT HAEMATOLOGIST HAEMOSTASIS
More informationDirect Oral Anticoagulants
Direct Oral Anticoagulants Holly Jahn, PharmD, CACP Objectives Identify the FDA approved indications for use, appropriate dosing, and monitoring parameters for each direct oral anticoagulant. Distinguish
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationSouthern Trust Anticoagulant Team
CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Anticoagulation- Primary Care Guidance for reviewing patients on DOACs Southern Trust Anticoagulant Team Haematology Acute
More informationComparison of novel oral anticoagulants (NOACs)
Comparison of novel oral anticoagulants (NOACs) For guidance for full information refer to individual SPCs available at www.medicines.org.uk Licensed indications for NOACs Prevention of stroke and systemic
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationAppendix IV - Prescribing Guidance for Apixaban
Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationPerioperative Management of Anticoagulation
Perioperative Management of Anticoagulation Presented By: Nibal R. Chamoun, PharmD, BCPS Clinical Assistant Professor, Clinical Coordinator Lebanese American University, School of Pharmacy Presented at:
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationDOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University
DOAC for VTE Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University No disclosures Direct Oral Anticoagulants Understand VTE and the ACCP s position on it List the DOACs available in the US
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationOutpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationWMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT
WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT - Entering orders for anticoagulation in Cerner Providers will enter individual orders (oneoffs)
More informationTim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio
Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio Medical University Objectives 1. 2. 3. 4. Review and discuss
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationNew Antithrombotic Agents
New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationNew and old anticoagulants. Anticoagulation Focus on Direct Oral Anticoagulants
Anticoagulation Focus on Direct Oral Anticoagulants Tzu-Fei Wang, MD Assistant Professor Department of Internal Medicine Division of Hematology The Ohio State University Wexner Medical Center Objectives
More informationDo s and Don t of DOACs DISCLOSURE
Do s and Don t of DOACs Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none Content Expert: Elsevier
More informationAnticoagulation Task Force
Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration
More informationPreventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE
Preventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE What Is Atrial Fibrillation? Atrial fibrillation also called AFib or AF is the most common abnormal heart rhythm, affecting an
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationUpdates in Management of Venous Thromboembolic Disease
Updates in Management of Venous Thromboembolic Disease November 7 th 2018 UHN Emergency Conference Susan Jenkins RN(EC) NP-Adult Thrombosis and Hemostasis Program University Health Network Disclosures
More informationThe DOACs. Update on Anticoagulation 10/20/2017. Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Edoxaban (Savaysa ) Objectives
Objectives Update on Anticoagulation JEFF REIST PHARMD, BCPS CLINICAL ASSOCIATE PROFESSOR UNIVERSITY OF IOWA COLLEGE OF PHARMACY At the conclusion of this program, the participant should be able to: List
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Services What percentage of time do patients on warfarin spend in therapeutic
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationThe Use of New Anticoagulants in the Elderly NOACs, DOACs,TOACs,TSOACs.
The Use of New Anticoagulants in the Elderly NOACs, DOACs,TOACs,TSOACs. Chris E. Holmes MD, PhD Assistant Director, Thrombosis and Hemostasis Program University of Vermont Dabigatran (Praxxada) Rivoraxaban
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationEdoxaban Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (NICE TA354)
Rationale for Initiation, Continuation and Discontinuation (RICaD) Edoxaban Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (NICE TA354) This document supports the
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationTSHP 2014 Annual Seminar 1
Debate: Versus the Rest of the World for Stroke Prevention in Non-valvular Atrial Fibrillation Matthew Wanat, PharmD, BCPS Clinical Assistant Professor University of Houston College of Pharmacy Clinical
More informationAre the days of Warfarin numbered?
2 nd SAVTE Symposium Are the days of Warfarin numbered? YES Dr. Mohamed A. Abdelaal, MD, FRCPath, FRCPI Consultant Haematologist King Abdulaziz Medical City - Jeddah, Saudi Arabia 1 3 May 2012, Casablanca,
More informationDrug Use Criteria: Direct Oral Anticoagulants
Texas Vendor Drug Program Drug Use Criteria: Oral Anticoagulants Publication History 1. Developed March 2017. 2. Revised February 2018. Notes: Information on indications for use or diagnosis is assumed
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationAn Overview of Non Vitamin-K Antagonist Oral Anticoagulants. Helen Williams Consultant Pharmacist for CV Disease South London
An Overview of Non Vitamin-K Antagonist Oral Anticoagulants Helen Williams Consultant Pharmacist for CV Disease South London Contents Drugs and drug classes Licensed indications and NICE recommendations
More informationAnticoagulation Beyond Coumadin
Anticoagulation Beyond Coumadin Saturday, September 21, 2013 Crystal Mountain Resort and Spa Pratik Bhattacharya MD, MPH Stroke Neurologist, Michigan Stroke Network; Assistant Professor of Neurology; Wayne
More informationDr Calum Young Cardiologist Tauranga
Dr Calum Young Cardiologist Tauranga 8:30-9:25 WS #93: New Oral Anticoagulant Drugs and Management of AF 9:35-10:30 WS #105: New Oral Anticoagulant Drugs and Management of AF (Repeated) GPCME 2016: Anticoagulation
More informationNovel Anticoagulant Drugs. by: Dr. M. Kamandi Fellowship of hematology and Oncology
Novel Anticoagulant Drugs by: Dr. M. Kamandi Fellowship of hematology and Oncology A-Novel Oral Anticoagulants A drug that is: safe and effective has predictable pharmacology has few drug drug and drug
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationClinical Guideline for Anticoagulation in VTE
Clinical Guideline for Anticoagulation in VTE These clinical guidelines are intended to provide evidence-based recommendations regarding the anticoagulation in patients with DVT and PE. Please note that
More informationOverview of anticoagulants David Perry
Chapter 2 Overview of anticoagulants David Perry Historically anticoagulation involved the use of heparin and its derivatives or warfarin. However, the past few years have seen the introduction of a number
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More information2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17
2017 Bryan Health Primary Care Conference Dale Hansen MD Bryan Heart 5/20/17 I have no financial disclosures or conflicts of interest Bridging Anticoagulation Primum Non Nocere 67 y.o. male with mechanical
More informationUpdate on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA
Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular Center UC San Diego The NOACS, chronologically Dabigatran:
More informationEdoxaban For preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (NICE TA 355)
Rationale for Initiation, Continuation and Discontinuation (RICaD) Edoxaban For preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (NICE TA 355) This document supports
More informationThey re Not So New Anymore Update on NOAC s (Novel Oral Anticoagulants)
They re Not So New Anymore Update on NOAC s (Novel Oral Anticoagulants) Daniel B. DiCola, MD Paul W. Ament, PharmD Daniel DiCola, MD ddicola@excelahealth.org Faculty: Latrobe Area Hospital, Excela Health
More informationLet s Gi e The So ethi g To Clot About: Controversies in Anticoagulation
Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Janna Beavers, MS, PharmD, BCPS Cardiology Clinical Pharmacy Specialist WakeMed Health & Hospitals Raleigh, NC March 13, 2018 Pharmacist
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Oral Anticoagulants Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oral Anticoagulant - Bevyxxa (betrixaban), Eliquis (apixaban), Pradaxa (dabigatran),
More informationNovel Oral An,coagulants: Prac,cal Aspects. Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015
Novel Oral An,coagulants: Prac,cal Aspects Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015 The New Oral An,coagulants (NOACs) The Non VKA Oral An,coagulants (NOACs)
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationAppendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
More informationA Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations
A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations Allison Bernard, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics October 25 th,
More informationEdoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF
Edoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF Traffic light classification- Amber 2 specialist initiation / recommendation Information
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationPRESENTATION TITLE. Case Studies
PRESENTATION TITLE Case Studies 1) SH is a 67 year old male. He has a history of type 2 diabetes, controlled hypertension and peripheral artery disease. He takes naproxen 500mg bd for arthritis and admits
More informationSurvey patients for Sx, signs of AF. Establish AF Dx. Evaluate & Tx underlying heart disease/other causes. Assess adequacy of rate or rhythm control
Suggested General Approach to Managing Atrial Fibrillation Survey patients for Sx, signs of AF Establish AF Dx ECG Holter Event monitor Implanted device (pacer) Determine & Tx stroke risk (CHA 2 DS 2 VASc)
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationNOACs in AF. Dr Fiona Stewart. Auckland Heart Group and Auckland DHB
NOACs in AF Dr Fiona Stewart Auckland Heart Group and Auckland DHB NOACS for AF True/False All patients should have a CHA 2 DS 2 VASc risk assessment on diagnosis of AF NOACS are more effective than warfarin
More informationPradaxa (dabigatran)
Pradaxa (dabigatran) Policy Number: 5.01.574 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Pradaxa
More informationChoosing and Managing Direct Oral Anticoagulants (DOACs)
Choosing and Managing Direct Oral Anticoagulants (DOACs) Ana G. Antun, MD, MSc Assistant Professor, Department of Hematology and Medical Oncology Winship Cancer Institute of Emory University 1 Outline
More informationNEW ZEALAND DATASHEET
1. PRODUCT NAME PRADAXA 75 mg hard capsules PRADAXA 110 mg hard capsules PRADAXA 150 mg hard capsules NEW ZEALAND DATASHEET 2. QUALITATIVE AND QUANTITATIVE COMPOSITION PRADAXA 75 mg hard capsules Each
More informationDavid Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy
David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy stewardw@etsu.edu At the conclusion of this program, the audience should
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationDirect Oral Anticoagulant Use in Older Adults Brian Skinner, PharmD
Direct Oral Anticoagulant Use in Older Adults Brian Skinner, PharmD Dr. Skinner serves as an Assistant Professor of Pharmacy Practice at Manchester University, and he is one of three Internal Medicine
More informationChallenges in Coagulation
Challenges in Coagulation Michael H. Rosove, MD Clinical Professor of Medicine UCLA Division of Hematology-Oncology April 30, 2016 Vitamin K Deficiency Vitamin K1 source from diet Vitamin K2 source from
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More informationNOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB
NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the
More informationMEDICATION MANAGEMENT IN VTE FROM CONVENTIONAL TO NEW
MEDICATION MANAGEMENT IN VTE FROM CONVENTIONAL TO NEW Presented by: David B. Coriale RPh. Pharm D BCPS Clinical Pharmacy Manger Oneida Healthcare Oneida, NY WWW.HEALTHUNITS.COM Presentation John is a
More informationProfessional Practice Minutes December 7, 2016
Professional Practice Minutes December 7, 2016 **New Opportunity for Patient Education** We can now request the educational videos we want our patients to watch after our visit. Video topics include colon
More informationTransitions of care in anticoagulated patients
Journal of Multidisciplinary Healthcare open access to scientific and medical research Open Access Full Text Article Transitions of care in anticoagulated patients Expert Opinion Franklin Michota Department
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationThe era of NOACs. (non-vitamin K oral anticoagulants) in Clinical Pharmacy : Patrick Tilleul
The era of NOACs (non-vitamin K oral anticoagulants) in Clinical Pharmacy : Patrick Tilleul Head Pharmacist, Pitié Salpêtrière hospital Associate professor Paris Sorbonne University Disclosure Patrick
More informationDOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT
DOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT A rose by any other name.. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationNanik Hatsakorzian Pharm.D/MPH
Pharm.D/MPH 2014 1 Therapeutics FDA indication & Dosing Clinical Pearls Anticoagulants Heparin Antiphospholipid antibody syndrome Cerebral thromboembolism Prosthetic heart valve Acute coronary syndrome
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationUpdates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017
Updates in Coagulation Thrombophilia testing and direct oral anticoagulants Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017 No conflicts of interest Introduction to thrombosis Hemostasis
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationNew Oral Anticoagulant Drugs in the Prevention of DVT
New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X
More informationManaging Perioperative Anticoagulation. Edie Shen MD
Managing Perioperative Anticoagulation Edie Shen MD Anticoagulation VKA Warfarin (Coumadin) DOACs Direct Thrombin Inhibitor Dabigatran (Pradaxa) Factor Xa Inhibitor Rivaroxaban(Xarelto) Apixaban(Eliquis)
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationNEWSLETTER DUE CARE PROGRAM. WINTER 2014 Summer 2015 COMMONLY ASKED QUESTION:
DUE CARE PROGRAM NEWSLETTER WINTER 2014 Summer 2015 Lisa Sather, RPh DUR Coordinator Mountain-Pacific Quality Health 3404 Cooney Drive Helena, MT 59602 406-457-5818 The DUE CARE PROGRAM, administered by
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More information